Approval · Notice of Compliance 21764 · 2019
MVASI: Notice of Compliance 21764
Issued January 17, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21764
- Date
- January 17, 2019
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- Labelling updates
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MVASI | Not yet assigned | — |
Medicinal ingredients
- BEVACIZUMAB 25 MG per ML
- BEVACIZUMAB 100 MG per 4ML